UNSPSC 51422345: Dexamethasone valerate

This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OI7CP949NN, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-valerate but more generally known as dexamethasone valerate, which bears US NIH Compound Identifier 63047. European Medicines Agency schedules Dexamethasone valerate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01619MIG.

Most nations, for tariff and trade purposes, schedule dexamethasone valerate under HS 29372200 and SITC 54153. As of Q4 2014, DEXAMETHASONE VALERATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)O.

UNSPSC 51422345 Dexamethasone valerate is a Commodity code for a specific pharmaceutical product, but the recent state and local contract opportunities tagged under it do not align with the code's nominal scope. The Seminole County, Florida IFB for Naloxone and Safe Drug Deactivation Systems and the Texas Health and Human Services Commission RFI for a Direct-to-Manufacturer Prescriptions program both address pharmaceutical procurement and pharmacy benefit management at the state and local level, yet neither involves dexamethasone valerate specifically. The mismatch suggests either tagging inconsistency in the source data or a broader pharmacy-products classification scheme at the issuing bodies. State and local purchasing under this code shows little activity directly related to dexamethasone valerate procurement.

The two recent opportunities reveal activity in pharmaceutical procurement among health departments and state health and human services commissions. Seminole County's IFB (posted June 30, 2026, response due July 26, 2023) seeks annual delivery of naloxone and drug deactivation systems to support community health initiatives, with quarterly delivery cycles and fixed-fee pricing. The Texas HHS Commission's RFI (posted April 3, 2026) explores vendor capacity for direct-to-manufacturer prescription programs to improve fulfillment efficiency outside traditional pharmacy benefit manager channels. Geographic activity appears limited to Florida and Texas in the recent record. Neither opportunity specifies set-aside designations or budget ranges that would signal pursuit priority under this code.